Giarc, I'm reading that ROW rights come after the PWS P2 trials and before NDA approval of Trofinetide. This table hasn't changed in the multiple presentations over the last several months? Irrespective I think we'll here something soon re: ROW rights maybe with a big pharma.
For me the below snippet is the really exciting thing that I'm eagerly looking forward to in the future
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)